Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (GEINOCANN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03529448
Recruitment Status : Not yet recruiting
First Posted : May 18, 2018
Last Update Posted : February 23, 2023
Medical Cannabis Bike Tour
Voices Against Brain Cancer
Information provided by (Responsible Party):
Grupo Español de Investigación en Neurooncología

Brief Summary:

Glioblastoma is the primary brain tumour with the worst prognosis: median survival is only 12 months despite the use of the most advanced treatments. In the past 10 years, survival in the treatment of this disease has not advanced significantly, with the postoperative standard being the administration of chemoradiotherapy with temozolomide, followed by 6 cycles of sequential chemotherapy with temozolomide.

Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumour effect with temozolomide and radiotherapy in preclinical glioma models. THC and CBD have a wide variety of biological effects by binding with and activating the type 1 and type 2 cannabinoid receptors (CB1 expressed in certain neuronal areas of the brain and CB2 expressed in the immune system and in glial cells). The activation of these receptors initiates a signalling pathway, called the endoplasmic reticulum stress response, which generates tumour cell autophagy by activating TRB3.

Given these data, the Spanish Group for Neuro-oncology (GEINO) proposes developing a phase Ib, open-label, multicenter, intrapatient dose-escalation clinical trial to assess the safety profile of the THC+CBD combination at a 1:1 ratio, adding temozolomide and radiotherapy in patients with newly-diagnosed glioblastoma.

The number of patients to be recruited is 30 over 6 months at 8 sites specialising in neuro-oncology.

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: TN-TC11G Drug: Temozolomide Oral Product Radiation: Radiotherapy Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Phase Ib, intra-patient dose escalation trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Estimated Study Start Date : July 2023
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TN-TC11G, radiotherapy and Temozolomide Oral Product

During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)

+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years.

Drug: TN-TC11G

TN-TC11G dose will be gradually increased as follows:

Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).

Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered.

Drug: Temozolomide Oral Product

During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.

At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles.

Other Name: Temozolomide

Radiation: Radiotherapy
All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
Other Name: STUPP

Primary Outcome Measures :
  1. THC-CBD Maximum tolerated dose [ Time Frame: 9 weeks ]
    After intra-patient dose escalation period, recommended dose of Glasdegib administeres with temozolamide during and after RT.

  2. Incidence of Treatment-Emergent Adverse Events [ Time Frame: 12 months ]
    Type and number or adverse events reported during THC-CBD treatment, based on the CTCAE reference criteria.

Secondary Outcome Measures :
  1. Antitumor activity of THC-CBD combination with temozolamide and radiotherapy [ Time Frame: 12 months ]
    Based on the tumor response in patients with measurable disease, after comparison of baseline characteristics and follow-up evaluations

  2. Overall survival [ Time Frame: 12 months ]
    Time between the start of treatment to death

  3. Progression free survival [ Time Frame: 12 months ]
    Time between the start of treatment and progression of disease

  4. Expression of Midkine [ Time Frame: 12 months ]
    Correlation of expression of midkine in peripheral blood and response to the experimental treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to understand and sign the informed consent document
  • Men or women ≥18 years and ≤70 years
  • Newly-diagnosed GB confirmed by biopsy or by resection in the 4-7 weeks before being registered in the trial.
  • Patients must have at least 15 slides without staining or a tissue block (frozen or paraffin-embedded) available from a previous biopsy or surgery (tumour sample previously archived).
  • Patients must have recovered from previous surgeries (time between surgery and inclusion in the study: 6 weeks).
  • Karnofsky Index ≥60%.
  • Adequate bone marrow reserve: haemoglobin ≥10 g/dL, WBC >3,000/mcL, absolute neutrophil count (ANC) ≥1,500 cells/μL, platelets ≥100,000 cells/μL.
  • Adequate liver function: Bilirubin <1.5 times the upper limit of normal (ULN); AST ≤2.5 x ULN
  • Creatinine clearance >60 ml/min/1.73 m2.
  • The study treatment's effects on the development of the human foetus are not known. For this reason, women of childbearing age and men must agree to use a suitable birth control method (hormonal, barrier, abstinence or surgical sterilisation) before inclusion in the study, for the duration of the study and for at least 3 months after completing the trial treatment. The definition of an effective method of birth control is based on the judgement of the principal investigator or their designee. If a woman is pregnant or there is suspicion that she might be pregnant while participating in the study, she must inform the trial doctor immediately. All women of childbearing age should have a negative pregnancy test (serum/urine) in the 2 weeks prior to the beginning of treatment.

Exclusion Criteria:

  • Presence of extracranial metastatic disease.
  • Any previous treatment for glioblastoma.
  • Patients who have had a Gliadel implant in the surgery.
  • Use of an enzyme-inducing antiepileptic drug. Patients receiving this type of drug must have a washout period of at least 7 days prior to study inclusion.
  • Previous abuse of cannabinoids.
  • Presence of any clinically significant gastrointestinal abnormality that may affect the intake, transit or absorption of the study drug, such as the inability to take medication in the form of oral tablets or solution.
  • Presence of any psychiatric or cognitive impairment that limits understanding or the signing of the informed consent and/or compromises compliance with the requirements of this protocol.
  • Significant or uncontrolled cardiovascular disease, including: 1. Myocardial infarction in the previous 12 months. 2. Uncontrolled angina in the previous 6 months. 3. Congestive heart failure in the previous 6 months. 4. Diagnosed or suspected congenital long QT syndrome. 5. History of ventricular arrhythmias of any clinically significant type (such as ventricular tachycardia, ventricular fibrillation or torsades de pointes). 6. QTc prolongation on an electrocardiogram prior to entry (>470 ms). 7. History of second- or third-degree heart block (these patients may be eligible if they carry pacemakers). 8. Heart rate <50/min on the baseline electrocardiogram. 9. Uncontrolled hypertension
  • Any patient with a history of significant cardiovascular disease, even if it is currently controlled, or who presents signs or symptoms that suggest impaired left ventricular function according to the investigator should have an assessment of left ventricular ejection fraction (LVEF) by ECCO or MUGA. If the LVEF in these circumstances is below the site's lower limit of normality or less than 50%, the patient will not be eligible.
  • History of any cancer, except in the following circumstances: Patients with a history of other malignancies are eligible if they have been disease-free for at least the last 3 years and if, in the investigator's opinion, there is a low risk of disease recurrence. People with the following cancers are eligible, even if they have been diagnosed and treated in the past 3 years: cervical carcinoma in situ and basal cell carcinoma.

Patients will not be eligible if there is evidence of another cancer that required therapy other than surgery in the past 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03529448

Layout table for location contacts
Contact: Federico Nepote +34 93 434 44 12
Contact: Verónica Roca +34 93 434 44 12

Layout table for location information
Hospital Universitario Virgen del Rocío
Sevilla, Andalucia, Spain, 41013
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Institut Català d'Oncología L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario Son Espases
Palma de Mallorca, Mallorca, Spain
Hospital del Mar
Barcelona, Spain, 08003
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Complejo Hospitalario Regional Virgen de las Nieves
Granada, Spain, 18004
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Regional Universitario de Malaga
Malaga, Spain
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Clínico Universitario de Salamanca
Salamanca, Spain, 37007
Contact: Investigator Selected by Sponsor   
Principal Investigator: Principal Investigator Selected by Sponsor         
Sponsors and Collaborators
Grupo Español de Investigación en Neurooncología
Medical Cannabis Bike Tour
Voices Against Brain Cancer
Layout table for investigator information
Principal Investigator: Manuel Benavides, M.D., Ph.D. Hospital Universitario y Regional de Málaga y Virgen de la Victoria
Layout table for additonal information
Responsible Party: Grupo Español de Investigación en Neurooncología Identifier: NCT03529448    
Other Study ID Numbers: GEINO-1601
2016-003216-12 ( EudraCT Number )
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: February 23, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Grupo Español de Investigación en Neurooncología:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents